Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases

Description

If an abbreviated HBP protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.

Conditions

Oligometastatic Disease, Liver Metastases, Colorectal Cancer

Study Overview

Study Details

Study overview

If an abbreviated HBP protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.

Evaluation of Liver MR with an Abbreviated Gadobenate Dimeglumine Hepatobiliary Phase Protocol in Comparison to Liver MR with Gadoxetate Disodium for the Detection of Hepatic Metastases

Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases

Condition
Oligometastatic Disease
Intervention / Treatment

-

Contacts and Locations

Aurora

University of Colorado Hospital, Aurora, Colorado, United States, 80045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Colorectal cancer patients
  • * Age 18-80 years
  • * No prior treatment including surgery
  • * Prior imaging with suspected liver metastasis
  • * Age \< 18 years or \> 80 years
  • * eGFR \< 30 ml/min/1.73 m2
  • * Previous reaction to gadolinium contrast agents
  • * History of claustrophobia or movement disorders likely to impact image quality
  • * Non-MR safe implants or metallic foreign bodies

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Colorado, Denver,

Samuel Chang, MD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

2026-12-09